ePrints

CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia

Lookup NU author(s): Judith Weiland, Dr Alex Elder, Dr Victoria Forster, Professor Olaf Heidenreich, Professor Hermann Josef Vormoor

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Over the last 20-30 years CD19 has gained attention as a potential target in the therapy of B-cell malignancies. In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL). This review will discuss the rationale behind targeting CD19 in BCP-ALL and its potential importance in BCP-ALL signaling pathways. Pediatr Blood Cancer 2015;62:1144-1148. (c) 2015 Wiley Periodicals, Inc.

Publication metadata

Author(s): Weiland J, Elder A, Forster V, Heidenreich O, Koschmieder S, Vormoor J

Publication type: Review

Publication status: Published

Journal: Pediatric Blood & Cancer

Year: 2015

Volume: 62

Issue: 7

Pages: 1144-1148

Print publication date: 01/07/2015

Online publication date: 08/03/2015

Acceptance date: 16/01/2015

ISSN (print): 1545-5009

ISSN (electronic): 1545-5017

Publisher: WILEY-BLACKWELL

URL: http://dx.doi.org/10.1002/pbc.25462

DOI: 10.1002/pbc.25462

Share